| Identification | Back Directory | [Name]
(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride | [CAS]
195733-43-8 | [Synonyms]
ABT627
ABT-627
ABT 627
A 147627.1
Abbott 147627
Atrasentan HCl
Unii-E4G31X93za
ABT-627 hydrochloride
A-147627 hydrochloride
ABT-627; ABT627; ABT 627
Atrasentan hydrochloride
(+)-A 127722 hydrochloride
Atrasentan hydrochloride [usan]
Atrasentan hydrochloride (ABT-627
Atrasentan hydrochloride, CID 159595
ABT-627; ABT627; ABT 627; ABBOTT 147627
(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride
3-Pyrrolidinecarboxylicacid,4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-,hydrochloride (1:1), (2R,3R,4S)-
3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, monohydrochloride, (2R,3R,4S)- | [Molecular Formula]
C29H38N2O6.HCl | [MDL Number]
MFCD13194884 | [MOL File]
195733-43-8.mol | [Molecular Weight]
547.08 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Soluble in DMSO | [form ]
Powder | [InChIKey]
IJFUJIFSUKPWCZ-FZVADPAUNA-N | [SMILES]
C1(=CC2=C(OCO2)C=C1)[C@@H]1[C@@H](C(=O)O)[C@H](C2C=CC(OC)=CC=2)N(CC(N(CCCC)CCCC)=O)C1.Cl |&1:9,10,14,r| |
| Hazard Information | Back Directory | [Description]
Atrasentan Hydrochloride(195733-43-8) is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.
| [Uses]
Atrasentan, a selective antagonist of the endothelin-A (ETA) receptor, binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation. | [Biological Activity]
Atrasentan is a selective endothelin ETA receptor antagonist with an IC50 of 0.2 nM for ETA compared to 190 nM for ETB receptors. It blocks blocks endothelin induced cell proliferation, and has been investigated as a possible treatment for prostate cancer, and more recently for therapy for diabetic kidney disease. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|